Press release 📈 Stocks 🌍 United States

Intellia Therapeutics Prepares for Lonvo-z Launch with March 2027 PDUFA Date

Intellia Therapeutics is preparing for the potential 2027 launch of lonvo-z, as the FDA continues its priority review of the HAE treatment without plans for an advisory committee meeting.

📅 November 12, 2026 🕐 1 min read

1 assets impacted (Stocks). Net bias: 1 Bullish, 0 Bearish, 0 Neutral. Strongest signal: NTLA ↑ 3/10 (60% confidence).

📊 Affected Assets (1)

NTLA

Bullish 🤖 60%

📅 Short-term 🌍 US · Explicit

The filing recaps that the FDA accepted the lonvo-z BLA for hereditary angioedema with priority review, a PDUFA goal date of March 10, 2027, and stated on September 3, 2026 that it does not plan an advisory committee meeting — a modest positive signal for approval odds. However, these milestones were already disclosed previously, and the deck adds no new clinical or financial figures, so the immediate price effect should be limited.

Catalysts

▲ PDUFA goal date of March 10, 2027 for lonvo-z approval decision
▲ FDA communication of September 3, 2026: no advisory committee planned for the BLA

Risk Factors

▼ Approval is still pending and not guaranteed before the 2027 PDUFA date
▼ Presentation contains only forward-looking statements with extensive risk warnings, no new data

🧭 Full analysis of these assets

🎯 Key Takeaways

The FDA set a PDUFA goal date of March 10, 2027, for the lonvo-z biologics license application.
On September 3, 2026, the FDA communicated that it does not currently plan to hold an advisory committee meeting regarding the application.
Intellia reported that 600+ patients have been dosed with its investigational in vivo CRISPR-based therapies to date.
The company achieved its first positive Phase 3 readout in hereditary angioedema on June 13, 2026.

📝 Executive Summary

Intellia Therapeutics is advancing its commercial readiness for lonvo-z, a one-time CRISPR-based therapy for hereditary angioedema (HAE). The company confirmed that the FDA has granted priority review for the biologics license application, with a PDUFA goal date set for March 10, 2027.

❓ FAQ

Does this filing contain any new results or figures for Intellia?

No, it is an investor presentation restating that the lonvo-z BLA is under FDA review with priority review and a PDUFA date of March 10, 2027.

Why is this mildly positive for the stock?

The FDA said it does not currently plan an advisory committee meeting, which the company presents as a sign the review is proceeding smoothly toward potential approval in 2027.

📰 Related Articles

🏷️ Tags

📰 Source

🔗 View Original Article